Compare ALEMBIC PHARMA with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs PROCTER & GAMBLE HEALTH - Comparison Results

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA PROCTER & GAMBLE HEALTH ALEMBIC PHARMA/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 16.4 15.7 104.5% View Chart
P/BV x 6.5 6.3 103.2% View Chart
Dividend Yield % 0.6 7.5 7.8%  

Financials

 ALEMBIC PHARMA   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
PROCTER & GAMBLE HEALTH
Dec-18
ALEMBIC PHARMA/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs6643,549 18.7%   
Low Rs4121,301 31.7%   
Sales per share (Unadj.) Rs208.7511.4 40.8%  
Earnings per share (Unadj.) Rs31.061.3 50.6%  
Cash flow per share (Unadj.) Rs37.174.0 50.1%  
Dividends per share (Unadj.) Rs5.50440.00 1.3%  
Dividend yield (eoy) %1.018.1 5.6%  
Book value per share (Unadj.) Rs144.2927.8 15.5%  
Shares outstanding (eoy) m188.5216.60 1,135.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.64.7 54.4%   
Avg P/E ratio x17.439.6 43.9%  
P/CF ratio (eoy) x14.532.8 44.3%  
Price / Book Value ratio x3.72.6 142.8%  
Dividend payout %17.7717.9 2.5%   
Avg Mkt Cap Rs m101,46140,257 252.0%   
No. of employees `000NA1.1 0.0%   
Total wages/salary Rs m7,4671,313 568.8%   
Avg. sales/employee Rs ThNM7,486.7-  
Avg. wages/employee Rs ThNM1,157.6-  
Avg. net profit/employee Rs ThNM897.2-  
INCOME DATA
Net Sales Rs m39,3478,490 463.5%  
Other income Rs m94244 38.5%   
Total revenues Rs m39,4418,734 451.6%   
Gross profit Rs m8,7361,482 589.6%  
Depreciation Rs m1,152211 545.6%   
Interest Rs m1840-   
Profit before tax Rs m7,4931,514 494.8%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m1,568563 278.7%   
Profit after tax Rs m5,8441,017 574.4%  
Gross profit margin %22.217.5 127.2%  
Effective tax rate %20.937.1 56.3%   
Net profit margin %14.912.0 123.9%  
BALANCE SHEET DATA
Current assets Rs m19,57715,343 127.6%   
Current liabilities Rs m14,8961,960 759.9%   
Net working cap to sales %11.9157.6 7.5%  
Current ratio x1.37.8 16.8%  
Inventory Days Days9049 184.1%  
Debtors Days Days4528 159.4%  
Net fixed assets Rs m27,0971,209 2,240.7%   
Share capital Rs m377166 227.1%   
"Free" reserves Rs m26,81115,235 176.0%   
Net worth Rs m27,18815,401 176.5%   
Long term debt Rs m4,9930-   
Total assets Rs m47,77817,595 271.5%  
Interest coverage x41.7NM-  
Debt to equity ratio x0.20-  
Sales to assets ratio x0.80.5 170.7%   
Return on assets %12.65.8 218.2%  
Return on equity %21.56.6 325.4%  
Return on capital %23.610.3 230.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,4531,636 1,188.8%   
Fx outflow Rs m6,0654,368 138.8%   
Net fx Rs m13,388-2,732 -490.1%   
CASH FLOW
From Operations Rs m8,120-1,304 -622.8%  
From Investments Rs m-7,55612,697 -59.5%  
From Financial Activity Rs m590-301 -196.5%  
Net Cashflow Rs m1,15311,093 10.4%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 2.9 18.2 15.9%  
FIIs % 9.1 1.0 910.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 29.1 47.8%  
Shareholders   49,328 28,591 172.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   JUBILANT PHARMOVA   PANACEA BIOTECH  GLENMARK PHARMA  GSK PHARMA  FRESENIUS KABI ONCO.  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY21); Net Profit Up 57.0% (Quarterly Result Update)

Aug 31, 2020 | Updated on Aug 31, 2020

For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


May 7, 2021 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS